UNSPSC 51383201: Clidanac

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H19ClO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UA6HM01WAK, chemically known as 6-chloro-5-cyclohexyl-2,3-dihydro-1h-indene-1-carboxylic acid but generally known as clidanac, which bears US NIH Compound Identifier 120108. European Medicines Agency schedules Clidanac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06659MIG.

UNSPSC 51383201 Clidanac is a Commodity code covering pharmaceutical products—specifically naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter medications—that state and local governments procure to support community health initiatives, pharmacy benefit programs, and public health emergency response. State and local issuing bodies soliciting under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. The work involves supplying finished pharmaceutical products through established distribution channels, with vendors responsible for compliance with Drug Supply Chain Security Act requirements, current Good Manufacturing Practices certification, FDA approval, and detailed product documentation including National Drug Codes and pricing structures. Contracts typically include requirements for insurance coverage, E-Verify compliance, and adherence to state and federal environmental regulations when federal funding is involved.

Recent activity shows geographic spread across Florida, Texas, and the upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building; bids closed July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, signaling early-stage procurement planning for pharmacy benefit optimization. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement and including Oregon participation, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson); proposals closed March 26, 2026, with contract performance beginning July 1, 2026. Evaluation weighted price competitiveness at 75 percent with additional scoring on administrative compliance, EDI capability, and pricing model flexibility.